[EBS] Emergent Biosolutions, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 33.6 Change: 0.1 (0.3%)
Ext. hours: Change: 0 (0%)

chart EBS

Refresh chart

Strongest Trends Summary For EBS

EBS is in the medium-term down -39% below S&P in 1 year. In the long-term up 47% above S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -42.32% Sales Growth - Q/Q-57% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.86% ROE6.59% ROI4.26%
Current Ratio5.05 Quick Ratio4.03 Long Term Debt/Equity0.77 Debt Ratio0.15
Gross Margin74.31% Operating Margin12% Net Profit Margin7.71% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11 M Cash From Investing Activities-9.08 M Cash From Operating Activities-65.87 M Gross Profit44.88 M
Net Profit-21.52 M Operating Profit-28.31 M Total Assets917.85 M Total Current Assets405.81 M
Total Current Liabilities80.3 M Total Debt251 M Total Liabilities379.97 M Total Revenue63.63 M
Technical Data
High 52 week73.24 Low 52 week39.92 Last close43.62 Last change-0.93%
RSI53.62 Average true range1.93 Beta0.83 Volume333.02 K
Simple moving average 20 days-0.45% Simple moving average 50 days-2.41% Simple moving average 200 days-20.53%
Performance Data
Performance Week-2.68% Performance Month-0.11% Performance Quart-6.58% Performance Half-25.55%
Performance Year-18.66% Performance Year-to-date-25.68% Volatility daily2.28% Volatility weekly5.11%
Volatility monthly10.46% Volatility yearly36.25% Relative Volume180.22% Average Volume378.21 K
New High New Low

News

2019-11-13 09:30:02 | EBS or ILMN: Which Is the Better Value Stock Right Now?

2019-11-07 13:22:48 | Edited Transcript of EBS earnings conference call or presentation 6-Nov-19 10:00pm GMT

2019-11-07 11:20:04 | Emergent EBS Beat Earnings in Q3, Vaccines Drive Sales

2019-11-06 19:05:12 | Emergent Biosolutions EBS Q3 Earnings and Revenues Beat Estimates

2019-11-06 16:05:00 | Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

2019-10-30 10:34:02 | Emergent Biosolutions EBS Earnings Expected to Grow: Should You Buy?

2019-10-25 09:33:02 | Can You Imagine How Chuffed Emergent BioSolutions's NYSE:EBS Shareholders Feel About Its 142% Share Price Gain?

2019-10-21 11:34:06 | Here’s What Hedge Funds Think About Emergent Biosolutions Inc EBS

2019-10-21 06:30:05 | Emergent BioSolutions to Host 2019 Analyst & Investor Day

2019-10-11 12:53:04 | Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

2019-10-10 09:34:05 | New Stocks on the Argus Focus List

2019-10-10 06:38:00 | Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

2019-10-09 06:30:00 | Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

2019-10-08 10:31:02 | Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

2019-09-27 06:35:14 | Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

2019-09-26 14:46:30 | Emergent lands $20M contract to develop chemical weapon antidote

2019-09-26 09:27:42 | Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

2019-09-25 16:15:00 | Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

2019-09-19 11:25:12 | Emergent BioSolutions Inc. NYSE:EBS Insiders Have Been Selling

2019-09-04 12:25:19 | Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement

2019-09-04 10:02:02 | Company News For Sep 4, 2019

2019-09-03 13:28:47 | Emergent lands federal contract for smallpox vaccine potentially worth more than $2B

2019-09-03 12:55:00 | Here's How Emergent BioSolutions Procured a Higher Price Today

2019-09-03 06:30:00 | Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, Smallpox Vaccinia Vaccine, Live Into the Strategic National Stockpile

2019-08-31 09:31:01 | Emergent Biosolutions EBS Down 0.9% Since Last Earnings Report: Can It Rebound?

2019-08-28 14:28:06 | Emergent's Vaccine Portfolio Aids Growth Amid Competition

2019-08-14 16:15:00 | Emergent BioSolutions to Participate in Series of Investor Conferences

2019-08-14 07:48:14 | Here's Why Emergent BioSolutions NYSE:EBS Has A Meaningful Debt Burden

2019-08-06 10:14:00 | Emergent BioSolutions Looks to the Second Half for Growth

2019-08-06 06:26:51 | Emergent BioSolutions Inc EBS Q2 2019 Earnings Call Transcript

2019-08-02 10:52:02 | Emergent EBS Earnings Miss in Q2, Revenues Beat Estimates

2019-08-02 03:39:32 | Edited Transcript of EBS earnings conference call or presentation 1-Aug-19 9:00pm GMT

2019-08-01 20:25:12 | Emergent Biosolutions EBS Q2 Earnings Lag Estimates

2019-08-01 16:05:00 | Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019

2019-07-30 16:42:29 | Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

2019-07-25 10:33:02 | Earnings Preview: Emergent Biosolutions EBS Q2 Earnings Expected to Decline

2019-07-18 06:30:00 | Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019

2019-07-09 06:08:15 | Here's What Emergent BioSolutions Inc.'s NYSE:EBS P/E Is Telling Us

2019-06-28 18:12:19 | Here’s What Hedge Funds Think About Emergent Biosolutions Inc EBS

2019-06-18 08:05:15 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-15 08:07:01 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-14 14:27:22 | Before You Buy Emergent BioSolutions Inc. NYSE:EBS, Consider Its Volatility

2019-06-10 08:07:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-05 13:20:58 | Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic

2019-06-05 09:52:00 | Emergent BioSolutions Looks Like It Will Get a Shot in the Arm

2019-06-04 18:58:00 | Don't Get Complacent: Cramer's 'Mad Money' Recap Tuesday 6/4/19

2019-06-04 16:05:00 | Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine

2019-06-04 11:52:03 | Emergent EBS Wins HHS Contract to Supply VIGIV Product

2019-06-04 08:06:06 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-03 14:53:59 | What Emergent’s latest $535M contract means for national ‘smallpox franchise’